Innate Pharma : Trésorerie à 141.6 M€ au S1 2018
>Résultats S1 2018 - Innate Pharma vient de publier ses chiffres au titre du S1 2018 : les produits opérationnels sur la période ressortent à 23.7 M€ (vs 21.2 M€ au S1 2017) et se composent principalement de i/ des revenus des accords de collaboration et de licence pour 16.9 M€ et ii/ du crédit impôt recherche pour 6.2 M€. La perte opérationnelle demeure stable à -15.7 M€ (contre -15.9 M€ en 2017) pour une perte nette à -16.2 M€. La position de trésorerie à fin juin 2...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.